{"id":"avt03","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Increased infection risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AVT03 is a monoclonal antibody that binds to and neutralizes TNF-α, a key inflammatory cytokine. By inhibiting TNF-α signaling, it reduces inflammatory responses in autoimmune and inflammatory conditions. As a biosimilar, it is designed to have equivalent efficacy and safety to the reference biologic adalimumab.","oneSentence":"AVT03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:06.335Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Denosumab","title":"Denosumab","extract":"Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone."},"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT05395091","phase":"PHASE3","title":"Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2022-08-23","conditions":"Osteoporosis, Postmenopausal","enrollment":532},{"nctId":"NCT05876949","phase":"PHASE1","title":"AVT03 With Xgeva in Healthy Male Subjects","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2023-07-21","conditions":"This is a Phase I Study Conducted in Healthy Volunteers","enrollment":208},{"nctId":"NCT05126784","phase":"PHASE1","title":"AVT03 With Prolia in Healthy Male Subjects","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2022-06-29","conditions":"Healthy Male Subjects","enrollment":209}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AVT03, Biosimilar Denosumab","AVT03 proposed Biosimilar to Denosumab"],"phase":"phase_3","status":"active","brandName":"AVT03","genericName":"AVT03","companyName":"Alvotech Swiss AG","companyId":"alvotech-swiss-ag","modality":"Biologic","firstApprovalDate":"","aiSummary":"AVT03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}